List of Tabrecta drug patents

Tabrecta is owned by Novartis Pharm.

Tabrecta contains Capmatinib Hydrochloride.

Tabrecta has a total of 5 drug patents out of which 0 drug patents have expired.

Tabrecta was authorised for market use on 06 May, 2020.

Tabrecta is available in tablet;oral dosage forms.

Tabrecta can be used as use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation.

Drug patent challenges can be filed against Tabrecta from May, 2024.

The generics of Tabrecta are possible to be released after 22 July, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(8 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 6, 2025
Orphan Drug Exclusivity (ODE) May 6, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in